Clinical Takeaway
In a controlled crossover trial of healthy males, CBD at both low and high single doses failed to directly reduce cortical excitability compared to placebo, suggesting its anti-seizure effects may depend heavily on pharmacokinetic interactions with co-administered medications like clobazam rather than acting alone on the brain. Clinicians should not assume CBD provides standalone neuroprotection or seizure suppression outside of its established adjunctive context. These findings reinforce the importance of polypharmacy considerations when evaluating CBD’s role in epilepsy management.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure management may depend primarily on drug-drug interactions rather than direct effects on neuronal excitability, which has important implications for patient selection and polypharmacy considerations in epilepsy treatment. Understanding CBD’s mechanism of action is essential for clinicians to optimize dosing strategies and predict efficacy in patients not taking interacting medications like clobazam. These findings help distinguish between CBD’s pharmacokinetic contributions and any potential direct anti-seizure properties, enabling more rational therapeutic decisions in managing drug-resistant epilepsy.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
? This well-designed crossover study challenges a common assumption about cannabidiol’s mechanism of action by demonstrating that CBD does not directly suppress cortical excitability in the way traditional antiepileptic drugs do, suggesting that its clinical efficacy in seizure disorders may rely more heavily on pharmacokinetic interactions with concurrent medications like clobazam rather than intrinsic neuronal effects. While the study’s controlled design is a strength, the relatively small sample size and focus on surrogate markers of excitability (rather than actual seizure outcomes) warrant caution in extrapolating findings to real-world clinical populations with heterogeneous seizure types and comorbidities. Additionally, the study cannot entirely exclude indirect mechanisms or effects mediated through non-cortical brain regions relevant to seizure suppression. For clinicians, this research underscores the importance of understanding CBD not as a monotherapy replacement for conventional antiepileptics but rather as an agent whose benefit may be optimized when used alongside compatible medications, and it
| |
Have thoughts on this? Share it:
